日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial

硫辛酸治疗进行性多发性硬化症:一项 II 期随机临床试验

Spain, Rebecca I; Paz Soldán, M Mateo; Freedman, Mark S; Repovic, Pavle; Solomon, Andrew J; Rinker, John Robert; Wallin, Mitchell T; Haselkorn, Jodie K; Stuve, Olaf; Gross, Robert H; Waslo, Carin Stewart; Hildebrand, Andrea; Morris, Cynthia D; Mitchell, Julie; Turner, Aaron P; Schwartz, Daniel L; Metz, Jill; Rooney, William

Diminishing returns of disease-modifying treatment in older participants of multiple sclerosis clinical trials

多发性硬化症临床试验中,老年参与者接受疾病修饰治疗的获益递减

Strijbis, Eva; Mostert, Jop; D'Haeseleer, Miguel; Moral, Ester; Brieva Ruiz, Luis; Comtois, Jacynthe; Killestein, Joep; Repovic, Pavle; McPherson, Tarrant; Cutter, Gary; Koch, Marcus

Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MS

选择适合多发性硬化症二期进展试验的患者:多发性硬化症二期临床试验的设计考虑因素

Koch, Marcus W; Camara-Lemarroy, Carlos; Strijbis, Eva; Mostert, Jop; Leavitt, Victoria M; Repovic, Pavle; Bowen, James D; Comtois, Jacynthe; Uitdehaag, Bernard; Cutter, Gary

Processing speed and memory test performance are associated with different brain region volumes in Veterans and others with progressive multiple sclerosis

处理速度和记忆测试表现与退伍军人和其他进行性多发性硬化症患者的不同脑区体积相关

Spain, Rebecca I; Hildebrand, Andrea; Waslo, Carin S; Rooney, William D; Emmons, Joshua; Schwartz, Daniel L; Freedman, Mark S; Paz Soldan, M Mateo; Repovic, Pavle; Solomon, Andrew J; Rinker, John 2nd; Wallin, Mitchell; Haselkorn, Jodie K; Stuve, Olaf; Gross, Robert H; Turner, Aaron P

The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials

MSIS-29 和 SF-36 作为继发进展型多发性硬化症试验的结局指标

Strijbis, Eva Mm; Repovic, Pavle; Mostert, Jop; Bowen, James D; Uitdehaag, Bernard Mj; Cutter, Gary; Koch, Marcus W

Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19

关于新冠疫情期间B细胞靶向疗法和其他多发性硬化症相关问题的播客

Shin, Robert K; Repovic, Pavle; Berger, Joseph R

Predicting Long-term Disability in Multiple Sclerosis: A Narrative Review of Current Evidence and Future Directions

预测多发性硬化症的长期残疾:现有证据和未来方向的叙述性综述

Weinstock-Guttman, Bianca; Sormani, Maria Pia; Repovic, Pavle

Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND

二甲富马酸酯对格拉替雷醋酸酯疗效欠佳后换用该药的复发型多发性硬化症患者(包括早期多发性硬化症患者)的疗效:RESPOND 研究的亚组分析

Repovic, Pavle; Robertson, Derrick; Kresa-Reahl, Kiren; Cohan, Stanley L; Su, Ray; Avila, Robin; Koulinska, Irene; Mendoza, Jason P

Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study

与富马酸二甲酯相比,富马酸二甲酯可改善胃肠道功能,并对生活质量产生积极影响:来自随机、双盲、III期EVOLVE-MS-2研究的结果

Wundes, Annette; Wray, Sibyl; Gold, Ralf; Singer, Barry A; Jasinska, Elzbieta; Ziemssen, Tjalf; de Seze, Jerome; Repovic, Pavle; Chen, Hailu; Hanna, Jerome; Messer, Jordan; Miller, Catherine; Naismith, Robert T

Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial

在 CHORDS IIIb 期试验的子研究中评估奥瑞珠单抗缩短输注时间的安全性

Bermel, Robert A; Waubant, Emmanuelle; Pardo, Gabriel; Bass, Ann; Repovic, Pavle; Newsome, Scott; Lindsey, John W; Kile, Deidre; Pradhan, Ashish; Musch, Bruno; Zabeti, Aram